Foghorn Therapeutics: Wedbush cuts to neutral from outperform; cuts target price to $2 from $10
FHTX•Wedbush cut its rating on Foghorn Therapeutics to neutral from outperform and lowered its target price to $2 from $10.
Related News
Gold steadies ahead of US payrolls data, heads for weekly decline
GLD•
Brixmor Property Group: Truist Securities assumes coverage with buy rating; price target $31
BRX•
Broadstone Net Lease raises to Buy from Hold; cuts target price to $21 from $22
BNL•
Essential Properties Realty Trust: Truist Securities cuts target price to $31 from $35
EPRT•
Corning: Truist Securities raises target price to $182 from $175
GLW•